Publications - Wellington Heart Ltd

Prof Scott Harding

Brunton-O’Sullivan MM, Holley AS, Bird GK, Kristono GA, Harding SA, Larsen PD. Examining variation and temporal dynamics of extracellular matrix biomarkers following acute myocardial infarction. Biomarkers in Medicine. 2021;16(3). Publised online 2 Feb 2022 https://doi.org/10.2217/bmm-2021-0531
Borrie A, Fairley S, Harding SA. First Experience Using the Sheathless Hyperion Guiding Catheter System Designed for Direct Insertion. Journal of Interventional Cardiology. 2022 Feb 22;2022. https://doi.org/10.1155/2022/5668728
Foley N, Sukmawati I, Harding SA. Inadvertent Lead Malposition: Prevention Is Better Than Cure. JACC:Case Reports. 2021 Nov 17;3(16):1753-5. https://www.jacc.org/doi/full/10.1016/j.jaccas.2021.09.008
Zebrauskaite A, Matsis P, Harding S. Closure of a Vein Graft Aneurysm, Complicated by an Acute Coronary Syndrome and Cardiogenic Shock. Authorea Preprints. 2021 Oct 25. DOI: 10.22541/au.163517162.20004152/v1
Wu EB, Kao HL, Lo S, et al. From reverse CART to antegrade wire access: a guide to externalisation, tip-in, rendezvous, and snaring from the APCTO club: Reverse CART to antegrade access. Asia Intervention. 2020;6(1):6-14. doi:10.4244/AIJ-D-19-00031
Wu EB, Brilakis ES, Mashayekhi K, Tsuchikane E, Alaswad K, Araya M, Avran A, Azzalini L, Babunashvili AM, Bayani B, Behnes M, Bhindi R, Boudou N, Boukhris M, Bozinovic NZ, Bryniarski L, Bufe A, Buller CE, Burke MN, Buttner A, Cardoso P, Carlino M, Chen JY, Christiansen EH, Colombo A, Croce K, de Los Santos FD, de Martini T, Dens J, di Mario C, Dou K, Egred M, Elbarouni B, ElGuindy AM, Escaned J, Furkalo S, Gagnor A, Galassi AR, Garbo R, Gasparini G, Ge J, Ge L, Goel PK, Goktekin O, Gonzalo N, Grancini L, Hall A, Hanna Quesada FL, Hanratty C, Harb S, Harding SA, Hatem R, Henriques JPS, Hildick-Smith D, Hill JM, Hoye A, Jaber W, Jaffer FA, Jang Y, Jussila R, Kalnins A, Kalyanasundaram A, Kandzari DE, Kao HL, Karmpaliotis D, Kassem HH, Khatri J, Knaapen P, Kornowski R, Krestyaninov O, Kumar AVG, Lamelas PM, Lee SW, Lefevre T, Leung R, Li Y, Li Y, Lim ST, Lo S, Lombardi W, Maran A, McEntegart M, Moses J, Munawar M, Navarro A, Ngo HM, Nicholson W, Oksnes A, Olivecrona GK, Padilla L, Patel M, Pershad A, Postu M, Qian J, Quadros A, Rafeh NA, Råmunddal T, Prakasa Rao VS, Reifart N, Riley RF, Rinfret S, Saghatelyan M, Sianos G, Smith E, Spaedy A, Spratt J, Stone G, Strange JW, Tammam KO, Thompson CA, Toma A, Tremmel JA, Trinidad RS, Ungi I, Vo M, Vu VH, Walsh S, Werner G, Wojcik J, Wollmuth J, Xu B, Yamane M, Ybarra LF, Yeh RW, Zhang Q. Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 Aug 24;78(8):840-853. doi: 10.1016/j.jacc.2021.05.055. PMID: 34412818.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. PMID: 34325831.
Harding SA, Webber B, Fairley S, Ormiston JA. Real-time intravascular ultrasound guidance: A novel technique for accurate placement of ostial stents. Harding SA, Webber B, Fairley S, Ormiston JA. Real-time intravascular ultrasound guidance: A novel technique for accurate placement of ostial stents. Catheter Cardiovasc Interv. 2021 Jun 16. doi: 10.1002/ccd.29830.
Brunton-O’Sullivan MM, Holley AS, Hally KE, Kristono GA, Harding SA, Larsen PD. A combined biomarker approach for characterising extracellular matrix profiles in acute myocardial infarction. Sci Rep. 2021 Jun 16;11(1):12705. doi: 10.1038/s41598-021-92108-z. PMID: 34135421.
Hally KE, Parker OM, Brunton-O’Sullivan MM, Harding SA, Larsen PD. Linking Neutrophil Extracellular Traps and Platelet Activation: A Composite Biomarker Score for Predicting Outcomes after Acute Myocardial Infarction. Thromb Haemost. 2021 May 13. doi: 10.1055/s-0041-1728763.
Kristono GA, Holley AS, Hally KE, Brunton-O’Sullivan MM, Shi B, Harding SA, Larsen PD. An IL-6-IL-8 score derived from principal component analysis is predictive of adverse outcome in acute myocardial infarction. Cytokine X. 2020 Oct 8;2(4):100037. doi: 10.1016/j.cytox.2020.100037.
Harding SA, Mowjood T, Fairley S. Ultra-low contrast percutaneous coronary intervention guided by optical coherence tomography complicated by coronary perforation. JACC: Case Reports. 2020 Dec 1;2(15):2429-31.
Kristono GA, Holley AS, Lakshman P, Brunton-O’Sullivan MM, Harding SA, Larsen PD. Association between inflammatory cytokines and long-term adverse outcomes in acute coronary syndromes: A systematic review. Heliyon. 2020 Apr 7;6(4):e03704. doi: 10.1016/j.heliyon. 2020. e03704.
Loh PH, Lassen JF, Jepson N, Koo BK, Chen S, Harding SA, Hu F, Lo S, Ahmad WAW, Ye F, Guagliumi G, Hiremath MS, Uemura S, Wang L, Whelan A, Low A. Asia Pacific Consensus Document on Coronary Bifurcation Interventions. EuroIntervention. 2020 Oct 9;16(9):e706-e714. doi: 10.4244/EIJ-D-19-00977.
Kristono GA, Holley AS, Harding SA, Larsen PD. White blood cell subtypes as predictors of adverse cardiac events. Coron Artery Dis. 2020 Aug;31(5):446-450. doi: 10.1097/MCA.0000000000000860.
Wu EB, Brilakis ES, Lo S, Kalyanasundaram A, Mashayekhi K, Kao HL, Lim ST, Ge L, Chen JY, Qian J, Lee SW, Harding SA, Tsuchikane E. Advances in CrossBoss/Stingray use in antegrade dissection re-entry from the Asia Pacific Chronic Total Occlusion Club. Catheter Cardiovasc Interv. 2020 Dec;96(7):1423-1433. doi: 10.1002/ccd.28607. Epub 2019 Nov 26.
Rinfret S, Harding SA. A new Japanese CTO algorithm: a step forward or backward? J Am Coll Cardiol. 2019 Nov 12;74(19):2405-2409. doi: 10.1016/j.jacc.2019.08.1048.
Hally KE, Bird GK, La Flamme AC, Harding SA, Larsen PD. Platelets modulate multiple markers of neutrophil function in response to in vitro Toll-like receptor stimulation. PLoS One. 2019 Oct 3;14(10):e0223444. doi: 10.1371/journal.pone.0223444. eCollection 2019.
Harding SA, Fairley S. Catheter induced coronary artery dissection: Keep calm and don’t inject. JACC Case Reports. 2019.
Foo FS, Lee M, Heaven D, Lever N, Sinclair S, Stiles MK, Harding S, Boddington D, Larsen P, Jackson R, Kerr AJ. Completeness of ANZACS-QI Cardiac Implanted DEVICE Registry and agreement with national datasets: ANZACS-QI 30. N Z Med J. 2019 Aug 16;132(1500):40-49.
Wu EB, Tsuchikane E, Ge L, Harding SA, Lo S, Lim ST, Chen JY, Lee SW, Qian J, Kao HL, Yan BP. Retrograde Versus Antegrade Approach for Coronary Chronic Total Occlusion in an Algorithm-Driven Contemporary Asia-Pacific Multicenter Registry: Comparison of Outcomes. Heart Lung Circ. 2019 Jul 2. pii: S1443-9506(19)31329-0. doi: 10.1016/j.hlc.2019.05.188.
Brilakis ES, Mashayekhi K, Tsuchikane E, et al. Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention: A Global Expert Consensus Document. Circulation. 2019 Jul 30;140(5):420-433. doi: 10.1161/CIRCULATIONAHA.119.039797.
Wu EB, Tsuchikane E, Lo S, Lim ST, Ge L, Chen JY, Qian J, Lee SW, Kao HL, Harding SA. Chronic total occlusion wiring: A state-of-the-art guide from the Asia Pacific Chronic Total Occlusion Club. Heart Lung Circ. Heart Lung Circ. 2019;28(10):1490-1500. doi: 10.1016/j.hlc.2019.04.004.
Hally KE, Holley AS, Kristono GA, Harding SA, Larsen PD. Immunoglobulin G levels predicts risk of recurrent adverse cardiovascular events in myocardial infarction patients. Acta Cardiol. 2019 May 10:1-6. doi: 10.1080/00015385.2019.1611189.
Matsuno S, Tsuchikane E, Harding SA, Wu EB, Kao HL, Brilakis ES, Mashayekhi K, Werner GS. Overview and proposed terminology for the reverse controlled antegrade and retrograde tracking (reverse CART) techniques. EuroIntervention. 2018 May 20;14(1):94-101. doi: 10.4244/EIJ-D-17-00867.
Wu EB, Tsuchikane E, Lo S, Lim ST, Ge L, Ji-Yan Chen, Qian J, Lee SW, Harding S, Kao HL. Retrograde algorithm for chronic total occlusion from the Asia Pacific Chronic Total Occlusion club. AsiaIntervention 2018;4:98-107, DOI: 10.4244/AIJ-D-17-00041
Hally KE, La Flamme AC, Harding SA, Larsen PD. Platelets regulate leucocyte responses to Toll-like receptor stimulation. Clin Transl Immunology. 2018 Jul 27;7(7):e1036. doi: 10.1002/cti2.1036. eCollection 2018.
Hally KE, La Flamme AC, Harding SA, Larsen PD. The effects of aspirin and ticagrelor on Toll-like receptor (TLR)-mediated platelet activation: results of a randomized, cross-over trial. Platelets. 2018 Jun 5:1-9. doi: 10.1080/09537104.2018.1479520.
O’Connor M, Hooks D, Webber M, Shi B, Morrison S, Harding S, Larsen P. Long-term single-center comparison of ICD lead survival: Evidence for premature Linox lead failure. J Cardiovasc Electrophysiol. 2018 Apr 14. doi: 10.1111/jce.13502.
Wilkins B, Hullikunte S, Simmonds M, Sasse A, Larsen PD, Harding SA. Improving the Prescribing Gap For Guideline Recommended Medications Post Myocardial Infarction. Heart Lung Circ. 2017 Nov 14. pii: S1443-9506(17)31490-7. doi: 10.1016/j.hlc.2017.10.025.
Matsuno S, Tsuchikane E, Harding SA, Wu EB, Kao HL, Brilakis ES, Mashayekhi K, Werner GS. Overview and Proposed Terminology for the Reverse Controlled Antegrade and Retrograde Tracking (reverse CART) Techniques. EuroIntervention. 2018 May 20;14(1):94-101. doi: 10.4244/EIJ-D-17-00867.
Harding SA, Wu EB, Lo S, Lim ST, Ge L, Chen, Quan J, Lee SW, Kao HL, Tsuchikane E. A New Algorithm for Crossing Chronic Total Occlusions from the Asia Pacific Chronic Total Occlusion Club. J Am Coll Cardiol Intv. 2017 Nov 13;10(21):2135-2143 doi: 10.1016/j.jcin.2017.06.071.
Fake A, Ranchord A, Harding S, Larsen P. Triple therapy versus dual antiplatelet therapy for patients with atrial fibrillation and acute coronary syndromes: A systematic literature review. Current Cardiology Reviews. 2017;13(4): p325-333), 2017.
Harding SA, Holley A, Wilkins B, Fairley S, Simmonds M, Larsen PD. Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor? Intern Med J. 2017 Nov;47(11):1298-1305. doi: 10.1111/imj.13595.
Hally KE, La Flamme AC, Larsen PD, Harding SA. Platelet Toll-like receptor (TLR) expression and TLR-mediated platelet activation in acute myocardial infarction. Thromb Res. 2017 Aug 1;158:8-15. doi: 10.1016/j.thromres.2017.07.031.
Larsen PD, Holley AS, Sasse A, Al-Sinan A, Fairley S, Harding SA. Comparison of Multiplate and VerifyNow platelet function tests in predicting clinical outcome in patients with acute coronary syndromes. Thromb Res. 2017 Apr;152:14-19. doi: 10.1016/j.thromres.2017.02.006. Epub 2017 Feb 10.
Holley A, Pitman J, Miller J, Harding S, Larsen P. Glutathione peroxidase activity and expression levels are significantly increased in acute coronary syndromes. J Investig Med. 2017 Jun;65(5):919-925. doi: 10.1136/jim-2016-000361. Epub 2017 Mar 15.
Matsis K, Holley A, Al-sinan A, Matsis P, Larsen PD, Harding SA. Differing clinical characteristics between young and older patients presenting with Myocardial Infarction. Heart Lung Circ. 2017 Jun;26(6):566-571. doi: 10.1016/j.hlc.2016.09.007. Epub 2016 Nov 11.
Holley AS, Miller JH, Larsen PD, Harding SA. Relationship between Glutathione Peroxidase, Platelet Reactivity, and Reactive Oxygen Species in an Acute Coronary Syndrome Population. Ann Clin Lab Sci. 2016 Dec;46(6):639-644
Hally KE, La Flamme AC, Larsen PD, Harding SA. Toll-like receptor 9 expression and activation in acute coronary syndrome patients on dual anti-platelet therapy. Thromb Res. 2016 Dec;148:89-95. doi: 10.1016/j.thromres.2016.10.026.
Chuluundorj D, Harding SA, Abernethy D, La Flamme AC. Glatiramer acetate treatment normalized the monocyte activation profile in MS patients to that of healthy controls. Immunol Cell Biol. 2017 Mar;95(3):297-305. doi: 10.1038/icb.2016.99. Epub 2016 Oct 3.
Fake AL, Harding SA, Matsis PP, Larsen PD. Pharmacological therapy following acute coronary syndromes in patients with atrial fibrillation: how do we balance ischaemic risk with bleeding risk? N Z Med J. 2016;12:39-49
Holley AS, Harding SA, Sasse A, Miller JH, Larsen PD. Reduced glutathione peroxidase activity predicts increased cardiovascular risk following an acute coronary syndrome. International Cardiovascular Forum Journal 2016 May 4 (Vol. 6).
Larsen PD, Kerr AJ, Hood M, Harding SA, Hooks D, Heaven D, Lever NA, Sinclair S, Boddington D, Tang EW, Swampillai J, Stiles MK; ANZACS-QI investigators. Pacemaker Use in New Zealand – Data From the New Zealand Implanted Cardiac Device Registry (ANZACS-QI 15). Heart Lung Circ. 2017 Mar;26(3):235-239. doi: 10.1016/j.hlc.2016.06.1206. Epub 2016 Jul 19.
Shi B, Harding S, Larsen P. Analysis of ECG measures of cardiac repolarization in relation to arrhythmic events in an implantable cardioverter defibrillator population. Ann Noninvasive Electrocardiol. 2016 Jun 13. doi: 10.1111/anec.12390.
Wolbinski M, Swain AH, Harding SA, Larsen PD. Out-of-hospital cardiac arrest patient characteristics: comparing ventricular arrhythmia and pulseless electrical activity. Heart Lung Circ. 2016;25:639-44.
Williams MJ, Harding SA, Devlin G, Nunn C, El-Jack S, Scott T, Lee M, Kerr AJ. National variation in coronary angiography rates and timing after an acute coronary syndrome in New Zealand (ANZACS-QI 6). N Z Med J. 2016;129:66-78.
Barr P, Smyth D, Harding SA, El-Jack S, Williams MJ, Devlin G, Stewart J, Flynn C, Lee M, Kerr AJ; ANZACS-QI investigators. Variation in Arterial Access for Invasive Coronary Procedures in New Zealand: A national analysis (ANZACS-QI 5). Heart Lung Circ. 2015; S1443-9506(15)01438-9. doi:10.1016/j.hlc.2015.10.009.
Furniss G, Jimenez A, Harding S. Balloon anchoring to exchange a displaced left ventricular lead over a wire without a coronary sinus guide catheter. 2015;17:1776
Johnston L, Harding SA, La Flamme AC. Comparing methods for ex vivo characterization of human monocyte phenotypes and in vitro responses. Immunobiology. 2015;220:1305-10. doi: 10.1016/j.imbio.2015.07.014.
Harding SA, Van Gaal WJ, Schrale R, Gunasekara A, Amerena J, Mussap CJ, Aylward PE. Practical experience with ticagrelor: an Australian and New Zealand perspective. Curr Med Res Opin. 2015 Jun 29:1-9.
Whitbourn R, Harding SA, Walton A. Symplicity multi-electrode radiofrequency renal denervation system feasibility study. EuroIntervention. 2015 May;11(1):104-9. doi: 10.4244/EIJV11I1A18.
Furniss GO, Liang M, Jimenez A, Harding S. Wire Externalisation for Left Ventricular Lead Placement in Cardiac Resynchronisation Therapy: A step-by-step guide. Heart Lung Circ. 2015 Nov;24(11):1094-103. doi: 10.1016/j.hlc.2015.04.173. Epub 2015 Jun 10.
Johnston LR, La Flamme AC, Larsen PD, Harding SA.Prasugrel inhibits platelet-enhanced pro-inflammatory CD4+ T cell responses in humans. Atherosclerosis. 2015;239:283-6. doi: 10.1016/j.atherosclerosis.2015.01.006.
Liang M, Devlin G, Harding SA. Radial Artery Spasm and Perforation: Simple Solutions for Challenging Cases. Heart Lung Circ. 2015;24:e71-4.
Camenzind E, Boersma E, Wijns W, Mauri L, Rademaker-Havinga T, Ordoubadi FF, Suttorp MJ, Al Kurdi M, Steg PG; PROTECT Steering Committee and Investigators. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. Eur Heart J. 2014 Aug 1;35(29):1932-48. doi:10.1093/eurheartj/ehu084.
Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA. 2015;313:1113-21. doi: 10.1001/jama.2015.1671.
Johnston LR, La Flamme AC, Larsen PD, Harding SA. Prasugrel inhibits platelet-enhanced pro-inflammatory CD4+ T cell responses in humans. Atherosclerosis. 2015;239:283-6.
Huo Y, Thompson P, Buddhari W, Ge J, Harding S, Ramanathan L, Reyes E, Santoso A, Tam LW, Vijayaraghavan G, Yeh HI. The Asia-Pacific ACS Medical Management Working Group. Challenges and solutions in medically managed ACS in the Asia-Pacific region: Expert recommendations from the Asia-Pacific ACS Medical Management Working Group. Int J Cardiol. 2014 Nov 28;183C:63-75. doi: 10.1016/j.ijcard.2014.11.195. [Epub ahead of print]
Larsen P, Johnston L, Holley A, La Flamme A, Smyth L, Chua E, Kennedy M, Harding S. Prevalence and significance of CYP2C19*2 and CYP2C19*17 alleles in a New Zealand acute coronary syndrome population. Intern Med J. 2015 Jan 13. [Epub ahead of print]
Webb IG, Yam ST, Cooke R, Aitken A, Larsen PD, Harding SA. Elevated Baseline Cardiac Troponin Levels in the Elderly – Another Variable to Consider? Heart Lung Circ. 2014 Aug 5. doi: 10.1016/j.hlc.2014.07.071. [Epub ahead of print]
Furniss G, Shi B, Jimenez A, Harding SA, Larsen PD. Cardiac troponin levels following implantable cardioverter defibrillation implantation and testing. Europace. 2015;17:262-6.
Shah N, Michel J, Aitken SA, Harding SA. Outcomes Following Conservative Management of Spontaneous Coronary Artery Dissection. Heart Lung Circ. 2014;23:e193-6.
Chuluundorj D, Harding SA, Abernethy D, La Flamme AC. Expansion and preferential activation of the CD14₊CD16₊ monocyte subset during multiple sclerosis. Immunol Cell Biol. 2014;92:509-17. doi: 10.1038/icb.2014.15.
ST-Elevation Myocardial Infarction Guidelines Group; New Zealand Branch of Cardiac Society of Australia and New Zealand. ST-elevation myocardial infarction: New Zealand Management Guidelines, 2013. N Z Med J. 2013;126:127-64.
VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014;311:252-62. doi: 10.1001/jama.2013.282836.
Din JN, Sarma J, Harding SA, Lyall K, Newby DE, Flapan AD. Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in patients with a previous myocardial infarction: a randomised controlled trial. BMJ Open. 2013;3:e003054. doi: 10.1136/bmjopen-2013-003054.
Shi B, Ferrier KA, Sasse A, Harding SA, Larsen PD. Correlation between vectorcardiographic measures and cardiac magnetic resonance imaging of the left ventricle in an implantable cardioverter defibrillator population. J Electrocardiol. 2014;47:52-8. doi: 10.1016/j.jelectrocard.2013.06.018.
Krebs D, Van Wissen KA, Harding SA, Ward MA, Marra B, Page R. An intervention trial for patients with hyperglycaemia and acute coronary syndrome: How effective is lifestyle advice? Prim Care Cardiovasc J. 2013;6:72-75. doi:10.3132/pccj.2013.008
Webster M, Harding S, McClean D, Jaffe W, Ormiston J, Aitken A, Watson T. First-in-human evaluation of a sirolimus-eluting coronary stent on an integrated delivery system: the DIRECT study. EuroIntervention. 2013;9:46-53. doi: 10.4244/EIJV9I1A8.
Padfield GJ, Din JN, Koushiappi E, Mills NL, Robinson SD, Cruden NL, Lucking AJ, Chia S, Harding SA, Newby DE. Cardiovascular effects of tumour necrosis factor α antagonism in patients with acute myocardial infarction: a first in human study. Heart. 2013;99:1330-5. doi: 10.1136/heartjnl-2013-303648.
Harding SA, Shah N, Briggs N, Sasse A, Larsen PD. Complex Transradial Percutaneous Coronary Intervention Using a Sheathless Guide Catheter. Heart Lung Circ. 2013;22:188-92. doi: 10.1016/j.hlc.2012.10.004.
Din JN, Archer RM, Harding SA, Sarma J, Lyall K, Flapan AD, Newby DE. Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers. Heart. 2013;99:168-174. doi: 10.1136/heartjnl-2012-302924.
Shi B, Harding SA, Jimenez A, Larsen PD. Standard 12-lead electrocardiography measures predictive of increased appropriate therapy in implantable cardioverter defibrillator recipients. Europace. 2013;15:892-8. doi: 10.1093/europace/eus360.
New Zealand 2012 guidelines for the management of non ST-elevation acute coronary syndromes. Non ST-Elevation Acute Coronary Syndrome Guidelines Group and the New Zealand Branch of the Cardiac Society of Australia and New Zealand. N Z Med J. 2012;125:122-47.
Johnston LR, Larsen PD, La Flamme AC, Harding SA. Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate® analyser. Platelets. 2013;24:303-7. Jun 11. doi: 10.3109/09537104.2012.694086.
Wilson D, Harding S. Predictors of more cranial or caudal axillary vein location to facilitate blind venous cannulation. Pacing Clin Electrophysiol. 2012;35:770.
TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297-309. doi: 10.1056/NEJMoa1205512.
Wilson D, Harding SA, Melton I, Lever N, Stiles M, Boddington D, Larsen PD. Geographic, ethnic and socioeconomic factors influencing access to Implantable-Cardioverter Defibrillators (ICDs) in New Zealand. Heart Lung and Circulation. Heart Lung Circ. 2012;21:576-81.
FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367:2375-84. doi: 10.1056/NEJMoa1211585.
Johnston LR, Larsen PD, La Flamme AC, Michel J, Simmonds M, Harding SA. Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes. Int J Cardiol. 2012 Mar 31. [Epub ahead of print]
Wilson D, Shi B, Harding S, Lever N, Larsen P. Implantable cardioverter defibrillators (ICDs): A long-term view. Intern Med J. 2011 Dec 29. [Epub ahead of print]
TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20-33.
PROTECT Steering Committee and Investigators. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet. 2012;380:1396-405. doi: 10.1016/S0140-6736(12)61336-1.
Burgess SN, Harding SA, Melton IC, Lever NA, Swain AH, Shi B, Larsen PD. An unmet need for implantable cardioverter-defibrillators in New Zealand. Europace. 2011;13:1299-303.
Burdess A, Nimmo AF, Campbell N, Harding SA, Garden OJ, Dawson AR, Newby DE. Perioperative platelet and monocyte activation in patients with critical limb ischemia. J Vasc Surg. 2010;52:697-703.
CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930-42.
Cruden NL, Harding SA, Flapan AD, Graham C, Wild SH, Slack R, Pell JP, Newby DE. Response to the letter regarding article, “previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery”. Circ Cardiovasc Interv. 2010;3:e17.
Ranchord AM, Prasad S, Seneviratne SK, Simmonds MB, Matsis P, Aitken A, Harding SA. Same-day discharge is feasible and safe in the majority of elderly patients undergoing elective percutaneous coronary intervention. J Invasive Cardiol. 2010 Jul;22(7):301-5.
Cruden NL, Harding SA, Flapan AD, Graham C, Wild SH, Slack R, Pell JP, Newby DE; Scottish Coronary Revascularisation Register Steering Committee. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery. Circ Cardiovasc Interv. 2010;3:236-42.
Larsen PD, De Silva P, Harding SA, Woodcock E, Lever NA. Use of implantable cardioverter defibrillators in the New Zealand context from 2000 to 2007. N Z Med J. 2010;123:76-85.
Ranchord AM, Prasad S, Matsis P, Harding SA. Paramedic-administered prehospital thrombolysis is safe and reduces time to treatment. N Z Med J. 2009;122:47-53.
McHale B, Harding SA, Lever NA, Larsen PD. A national survey of clinician’s knowledge of and attitudes towards implantable cardioverter defibrillators. Europace. 2009;11:1313-6.
Samer H, Larsen P, Galletly DC, Harding SA. Peri-operative management of antiplatelet agents. Australian and New Zealand Journal of Surgery. ANZ J Surg. 2009;79:521-5.
Lever NA, Larsen PD, Dawes M, Wong A, Harding SA. Are our medical graduates in New Zealand safe and accurate in ECG interpretation? New Zealand Med J. 2009;122.
Cruden NL, Harding SA, Newby DE. Coronary stents: surgery and stent thrombosis. BMJ 2008;337: a2074.
Orsbourn G, Lever N, Harding SA. Use of tunnelled active fixation leads allows reliable prolonged temporary pacing. Intern Med J. 2008;38:735-8.
Ranchord AM, Harding SA, Pidgeon G. Medications for the secondary prevention of ischaemic heart disease and heart failure are under utilised in dialysis patients. Intern Med J. 2008;38:361-4.
Woodhead J, Harding SA, Simmonds M, Dee S, McBride-Henry K. Premedication for cardiac catheterization and percutaneous coronary intervention: does it increase vascular access site complications? J Cardiovasc Nurs. 2007;22:466-71.
Harding SA, Din JN, Sarma J, Jessop A, Weatherall M, Fox KA, Newby DE. Flow cytometric analysis of circulating platelet-monocyte aggregates in whole blood: methodological considerations. Thromb Haemost. 2007;98:451-6.
Din JN, Harding SA, Valerio CJ, Sarma J, Lyall K, Riemersma RA, Newby DE, Flapan AD. Dietary intervention with oil rich fish reduces platelet-monocyte aggregation in man. Atherosclerosis. 2008;197:290-6.
Harding SA, Anscombe R, Weatherall M, Prasad S, Lever N, Krebs J. Abnormal glucose metabolism and features of the metabolic syndrome are common in patients presenting for elective cardiac catheterization. Internal Med J 2006;36:759-64.
Harding SA, Din JN, Sarma J, Josephs DH, Fox KA, Newby DE. Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin. Heart. 2006;92:1635-8.
Harding SA, Sarma J, Din JN, Maciocia PM, Newby DE, Fox KA. Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus. Heart 2006;92:1335-7.
Harding SA. Vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention. Heart 2006;92:1191-3.
Robinson SD, Harding SA, Cummins P, Din JN, Sarma J, Davidson I, Fox KAA, Boon NA, Newby DE. Functional interplay between platelet activation and endothelial dysfunction in patients with coronary heart disease. Platelets 2006;17:158-62.
Cruden NLM, Graham C, Harding SA, Ludlam CA, Fox KAA, Newby DE. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction. Thromb Res. 2006;118:189-97.
Harding SA, Sommerfield AJ, Sarma J, Twomey PJ, Newby DE, Frier BM, Fox KA. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 2004;176:321-5.
Hillis GS, Pearson CV, Harding SA, Sutherland S, Ludlam CA, Marioni JC, Prescott RJ, Fox KA, Flapan AD. Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study. Am Heart J 2004;148:72-9.
Harding SA, Sarma J, Josephs DH, Cruden NL, Din JN, Twomey PJ, Fox KA, Newby DE. Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation 2004;109:1926-9.
MacNeill BD, Harding SA, Bazari H, Patton KK, Colon-Hernadez P, DeJoseph D, Jang IK. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv 2003;60:458-61.
Wong P, Harding SA, Walters DL, Jang IK. The effect of glycoprotein IIb/IIIa receptor inhibitor, tirofiban, on the microcirculation and silent ischaemia in patients undergoing high-risk coronary stenting. J Thromb Thrombolysis 2003;16:163-6.
Harding SA, Fox KAA. Clopidogrel in Coronary Artery Disease. British J Cardiol 2002;9:S8-12.
Harding SA, Boon NA, Flapan AD. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet 2002;360:255.
Walters DL, Harding SA, Walsh CR, Wong P, Pomerantsev E, Jang IK. Acute coronary syndrome is a common presentation of in-stent restenosis. Am J Cardiol 2002;89:491-4.
Harding SA, McKenna CJ, Flapan AD, Boon NA. Long-term clinical safety and efficacy of NIROYAL vs. NIR intracoronary stent. Catheter Cardiovasc Interv 2001;54:141-5.
Harding SA, Walters DL, Palacios IP, Oesterle SN. Adjunctive pharmacotherapy for coronary stenting. Curr Opin Cardiol 2001;16:293-9.
Walters DL, Harding SA, Palacios IP, Oesterle SN. The use of mechanical devices as adjuncts to intracoronary stenting. Curr Opin Cardiol 2001;16:300-5.
Wong P, Harding S, Walters D, Hull ML, Jang IK. Vascular complications after haemostatic puncture closure device (Angio-Seal) are not higher in overweight patients. J Invasive Cardiol 2001;13:623-5.
Harwood M, Harding S, Beasley R, Frankish P. Asthma following royal jelly. NZ Med J 1996;109:32